Navigation Links
Chroma to Present Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
Date:11/30/2007

OXFORD, England, Nov. 30 /PRNewswire/ -- Chroma Therapeutics Limited announced today that it will report efficacy data from a Phase I clinical trial of its oral, once-daily experimental cancer therapy CHR-2797 at the forthcoming American Society of Hematology (ASH) meeting. CHR-2797 is the only oral aminopeptidase inhibitor currently in clinical development. The company will also be presenting the results of various preclinical studies. Details of the presentations are as follows:

Abstract # 443: oral presentation

Title: A Phase I Study of CHR-2797, an Orally Active Aminopeptidase

Inhibitor in Elderly and/or Treatment Refractory Patients with Acute

Myeloid Leukemia

Location and timing: Acute Myeloid Leukemias: Therapy, excluding

Transplantation-Novel Therapies, Rooms A411-A412: Monday December 10,

2007, 13:30-15:00 Eastern Standard Time

Presenter: Dr Faith Davies (Royal Marsden Hospital, London, UK)

Abstract # 1608, Poster # 762

Title: Cellular Aminopeptidase Inhibition as a Target for the Therapy of

AML by the Novel Agent CHR-2797

Location and timing: Poster Session I, Hall B4: Saturday, December 8,

2007, 17:30-19:30 Eastern Standard Time

Presenter: Dr Chris Jenkins (University Hospital, Cardiff, UK)

Abstract # 2505, Poster # 695

Title: Aminopeptidase Inhibition as a Targeted Treatment Strategy in

Myeloma

Location and timing: Poster Session II, Hall B4: Sunday, December 9,

2007, 18:00-20:00, Eastern Standard Time

Presenter: Dr Faith Davies (Royal Marsden Hospital, London, UK)

The ASH posters will be available at the company's website, http://www.chromatherapeutics.com following the above presentations.

Enquiries

Chroma Therapeutics Limited

Ian Nicholson Chief Executive Officer +44 (0)1235 829120

Richard Bungay Chief Financial Officer

Brunswick

Jon Coles +44 (0)20 7404 5959

Justine McIlroy

About aminopeptidases and CHR-2797

Aminopeptidases are a family of intracellular enzymes involved in the supply of amino acids that are essential for cell growth. Inhibition of aminopeptidases has been shown to halt cell growth or cause apoptosis (cell death) in a large number of cancer cell lines. Conversely, normal (non-tumour) cell lines have been shown to be insensitive to aminopeptidase inhibition. CHR-2797 is a potent inhibitor of aminopeptidases that has demonstrated strong preclinical efficacy as monotherapy and has also been shown to strongly synergise with a number of leading cancer therapies in a range of cancer cells.

About Chroma Therapeutics

Chroma Therapeutics, based in Oxford (UK), is a drug discovery and development company focused in the fields of oncology and inflammatory disorders. Chroma is building a broad pipeline of first- or best-in-class treatments utilising its expertise in chromatin biology and its novel intracellular accumulation technologies, which include the ability to selectively target drugs to macrophages. Chroma is backed by a number of leading specialist investors, including Abingworth, Essex Woodlands, Gilde, Nomura Phase4 and The Wellcome Trust.

More information about Chroma can be found at http://www.chromatherapeutics.com.


'/>"/>
SOURCE Chroma Therapeutics Limited
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Chromatin remodeling complex connected to DNA damage control
2. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
3. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
4. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
7. AtriCure to Present at Roth Capital Partners 2007 New York Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. MDS to Present at Thomas Weisel Partners Healthcare Conference
10. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
11. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , ... January 20, 2017 , ... Source Vitál Apothecary, ... 100 percent pure essential oils, announced the company had a successful visit to the ... annual ECRM event gives companies that work in the nutritional, sports and health industries ...
(Date:1/20/2017)... ... January 20, 2017 , ... Lice Troopers, the lice removal company ... with school-aged children since the holiday season. , “It happens every year around ... sharing hugs and taking photos, which is the head-to-head gateway that lice need to ...
(Date:1/20/2017)... ... , ... Michael and Betsy Brauser celebrated 5 years of Betsy’s participation in ... has been life-saving as she has been on the trial for more than ... with ovarian cancer in 2009. She underwent standard chemotherapy but a year later went ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is Greater ... of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than ... her career as an educator interacting with countless women who had little knowledge of ...
(Date:1/20/2017)... ... ... a fine examination of how God handles sin, including how to let go of ... who, for over ten long years has been waiting to release this powerful insight about ... has been serving the Lord for over twenty years, and he has been preaching and ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... 20, 2017 Research and Markets has ... Type ([CBC, HGB/HCT, BMP, BUN Creatinine, Electrolyte Testing, HbA1c Testing, Comprehensive ... Segment Forecasts, 2013 - 2024" report to their offering. ... The global clinical ... 2024 Introduction of innovative solutions on the grounds of ...
(Date:1/20/2017)... , January 20, 2017 Stock-Callers.com ... (NASDAQ: SGYP ), Novo Nordisk A/S (NYSE: ... ), and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX ... on Thursday, January 19 th , 2017, finishing near its ... Care Index dropped over 0.7%, while shares of health care ...
(Date:1/20/2017)... 2017 Wells Specialty Pharmacy announces the acquisitions and ... in Winter Park, Florida and Pharm-EZ ... Operations have been consolidated into the 3796 Howell Branch Road ... announce that Chad Tomlinson , former Vice President of ... immediately. Mr. Tomlinson is a Graduate of Florida State University ...
Breaking Medicine Technology: